Myocarditis and Pericarditis After Vaccination for COVID-19

This study investigates the incidence of myocarditis and pericarditis emergency department or inpatient hospital encounters before COVID-19 vaccine availability (January 2019–January 2021) and during a COVID-19 vaccination period (February-May 2021) in a large US health care system.

Saved in:
Bibliographic Details
Published inJAMA : the journal of the American Medical Association Vol. 326; no. 12; pp. 1210 - 1212
Main Authors Diaz, George A, Parsons, Guilford T, Gering, Sara K, Meier, Audrey R, Hutchinson, Ian V, Robicsek, Ari
Format Journal Article
LanguageEnglish
Published United States American Medical Association 28.09.2021
Subjects
2019-nCoV Vaccine mRNA-1273
Ad26COVS1
Adult
Aged
BNT162 Vaccine
Comments
Confidence Intervals
Coronaviruses
COVID-19
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - adverse effects
Emergency medical care
Emergency medical services
Female
Health care
Heart diseases
Hospitalization - statistics & numerical data
Humans
Immunization
Incidence
Letter
Letters
Los Angeles - epidemiology
Male
Middle Aged
Montana - epidemiology
Myocarditis
Myocarditis - epidemiology
Myocarditis - etiology
Online First
Oregon - epidemiology
Pericarditis
Pericarditis - epidemiology
Pericarditis - etiology
Poisson Distribution
Research Letter
Time Factors
Vaccination
Vaccines
Washington - epidemiology
Oregon
Montana
Los Angeles
Washington
Online AccessGet full text

Cover

More Information
Summary:This study investigates the incidence of myocarditis and pericarditis emergency department or inpatient hospital encounters before COVID-19 vaccine availability (January 2019–January 2021) and during a COVID-19 vaccination period (February-May 2021) in a large US health care system.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0098-7484
1538-3598
1538-3598
DOI:10.1001/jama.2021.13443